TAMPA, Fla., Feb. 15, 2008 (PRIME NEWSWIRE) -- RxPC Inc. trumps the leading Canadian online pharmacy Generic Atorvastatin (Lipitor) price by 36.6%. This announcement is great news for U.S. Citizens as our vendor reduced cost of retail Generic Atorvastatin (Lipitor) 20mg / 30 Pills is $29.84. This saves U.S. Citizens 36.6% off the leading online Canadian retail pharmacies Generic Atorvastatin 20mg / 30 pills priced at $47.08*.
RxPC Inc. is building awareness of our inexpensively priced generic Atorvastatin 20mg / 30 pills for $29.84 from our vendor pharmacies. The pricing is available direct to the under and uninsured as members of www.rxpcinc.com. The savings is up to 76% off the average retail pharmacy price in the United States.
Peter Fiorillo commented, "Our leadership pricing comes with great responsibility as health care goes direct for maximum savings to U.S. citizens. The determination to build affordable health care and a healthier life is being realized with U.S. citizens' continued support. Thank you."
U.S. Citizens are encouraged to register for membership to purchase and support the expansion of www.rxpcinc.com
RxPC provides access to pharmaceutical medications and laboratory tests online and through licensed mail-order pharmaceutical facilities and CLIA-approved patient service centers. Our scalable ordering solution of brand-name and generic medications is right for Individuals, Corporations, Unions, or any citizen organization in the United States. The complimented offering are supported by access to over 1,000 preventative lab tests, with access to 4,000+ CLIA-approved patient service centers for lab testing. RxPC Inc. estimates that more than 151 million United States citizens would benefit from these company programs.
RxPC Inc. is not engaged in any outbound telemarketing, faxing, or email marketing campaigns.
The RxPC Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4702
Safe Harbor Statement:
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including those about the company's future expectations, revenues and earnings, and all other forward-looking statements (i.e. operational results and sales) are subject to assumptions and beliefs based on current information known to the company and factors that are subject to uncertainties, risk and other influences, which are outside the company's control, and may yield results differing materially from those anticipated. We undertake no obligation to update any forward-looking statements to reflect events or circumstances that may arise after the date of this release.
Notes: $47.08* is the displayed price on Canadadrugs.com as of
2/15/2008 at 12:31pm